Sanofi priced an offering of $2 billion of notes, which will be conducted in two tranches.

The Paris-based drugmaker is offering $1 billion of 3.375% fixed rate notes due June 19, 2023, and $1 billion of 3.625% fixed rate notes due June 19, 2028.

Net proceeds will go toward general corporate purposes, including repayment of existing debt.

Barclays Capital Inc. and Morgan Stanley & Co. LLC acted as global coordinators for the offering, with Barclays Capital Inc., Citigroup Global Markets Inc., Deutsche Bank Securities Inc., Morgan Stanley & Co. LLC and MUFG Securities Americas Inc. as joint book runners.